foto
LATEST NEWS

 OctoPlus announces 2010 first half-year results



WEBCAST HALF-YEAR RESULTS

Click here to access the webcast of 6 August 2010



OCTOPLUS OPENED NYSE EURONEXT

In celebration of OctoPlus' 15 year anniversday, CEO Simon Sturge and CFO Susan Swarte opened the financial markets in Amsterdam on Tuesday 27 July



OCTOPLUS ANNUAL REPORT 2009
VIEW OUR WEB SEMINARS
OCTO SHARE PRICE
HOME dashNL dash CONTACT

 

CLINICAL MANUFACTURING

OctoPlus has been operating a clinical manufacturing plant in Leiden, the Netherlands since 2000. The activities of this plant are focused on small-scale clinical production.

In 2008, our facilities have been expanded with more laboratories, offices, and an additional cGMP plant. Both the existing cGMP plant and the recent expansion comprise dedicated formulation areas and areas for both production and fill and finish of parenteral dosage forms.

  

 

 

 

 

 

 

 


Our Leiden headquarters also comprise laboratories dedicated to analytical activities such as stability testing and release testing.

OctoPlus offers unique development and manufacturing expertise in the area of complex formulations, such as liposomes and microspheres, for a large range of biologicals (proteins, vaccines, antibodies, siRNA, DNA) and low-solubles (peptides, small molecules).

We collaborate with large and small biotech and pharma companies worldwide, on development of their products from pre-clinical to late-stage clinical phases.

For more information on OctoPlus' clinical manufacturing services, visit our Fill & Finish manufacturing page, or download our Clinical Manufacturing factsheet.